Clinical Trial Update: Monoclonal Antibody Therapy Plus Sargramostin in Treating Patients With Advanced Neuroblastoma [Phase 2]

View source ↗

Summary

This document reports a Phase 2 trial evaluating a monoclonal antibody therapy in combination with sargramostim for advanced neuroblastoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroblastoma

Drugs mentioned

• 3F8 anti-GD2 monoclonal antibody (3F8 anti-GD2 monoclonal antibody)
• sargramostim (sargramostim)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Neuroblastoma | Phase 2 | Status: COMPLETED